Based on this finding, all Phase 3 TRIUMPH trials use 2 mg as the universal starting dose, with the first escalation to 4 mg occurring at week 5
Lincoff et al., 2023, PMID: 37952131) and tirzepatide 15mg (20.9% at 72 weeks) by clinically meaningful margins
This characteristic facilitates the development of AAV variants with specific tissue tropism for research purposes
This individualised approach is more effective than following generic calorie ranges, as requirements vary considerably based on factors such as height, weight, age, sex, and activity level
We also kept in mind how often we had to reapply each one throughout the day and noted what activities we did while wearing it (like working out, going out for the night or wearing it to work)
Results were expressed as percentage of phagocytosing PMN or PBMC and as calculated absolute phagocytosing PMN and PBMC by offsetting with cell counts